This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D68.2 | Special Copayment Reduction: V009 (rare disease) |
| B. Synonyms | Hageman factor deficiency, Contact factor deficiency, F12 deficiency |
| C. Adult onset | Almost none — because there is no clinical bleeding tendency, the typical route is incidental discovery in adulthood through APTT prolongation before surgery; diagnosis from spontaneous symptoms is extremely rare, and instead a possible increase in thrombotic risk is discussed. |
| 1. History | Discovered incidentally on John Hageman's preoperative testing in 1955. Hageman later died of thrombotic pulmonary embolism—a history symbolizing the irony of FXII deficiency. |
| 2. Causes | Pathogenic variants in the F12 gene at chromosome 5q35.3; autosomal recessive inheritance; various missense, nonsense and splicing variants. |
| 3. Genetics | F12 gene 5q35.3, 14 exons, mature protein 596 amino acids. Association with HAE (hereditary angioedema)—abnormality of the FXII→kallikrein→bradykinin pathway. |
| 4. Epidemiology | Prevalence in the general population estimated at about 1 in several hundred thousand; complete deficiency is very rare; occurs equally in males and females. |
| 5. Pathophysiology | FXII is the initiating factor of the intrinsic (contact activation) pathway but is not essential for in vivo hemostasis; involved in the bradykinin pathway and regulation of innate immunity; possible prothrombotic role discussed. |
| 6. Symptoms | Characterized by no clinical bleeding; no abnormal bleeding even with surgery, trauma or childbirth; virtually no cases discovered through spontaneous symptoms. |
| 7. Signs | Marked APTT prolongation (often 60 seconds or more), normal PT·TT·platelets·bleeding time; FXII:C very low or unmeasurable. |
| 8. Screening | Incidental discovery through preoperative APTT prolongation is typical; differentiating tests for contact factors (FXII, PK, HMW kininogen); investigation of family history of HAE. |
| 9. Diagnosis | APTT prolongation → shortening with prolonged plasma contact activation time (characteristic of FXII deficiency) → mixing test → single-factor FXII:C measurement → F12 gene analysis. |
| 10. Treatment | No bleeding treatment needed; preoperative prophylactic administration also not recommended; no approved therapy to correct FXII deficiency itself; separate management when accompanied by HAE. |
| 11. Prognosis | Normal life without bleeding complications; whether thrombotic risk is increased is under debate; no effect on life expectancy. |
| 12. Prevention | Preoperative hematology consultation to prevent unnecessary FFP transfusion; management of thrombotic risk factors; HAE prophylaxis; family genetic counseling. |
| 13. References | First description by Ratnoff OD & Colopy JE in 1955 and 10 or more other key references. |
The history of coagulation factor XII deficiency begins in 1955 in Cleveland, Ohio, USA. John Hageman (1928–1968), who was then working as a railroad freight car inspector, visited the hospital for an entirely different reason, and routine preoperative testing found that his activated partial thromboplastin time (APTT) was very markedly prolonged. The hematologists in charge of the testing, Oscar D. Ratnoff and James E. Colopy, traced the cause of this unusual coagulation test finding and confirmed that a previously unknown new coagulation factor was deficient, naming this factor Hageman factor after the surname of the first patient. Their study was published in the same year in the Journal of Clinical Investigation and recorded as an important discovery in coagulation medicine. In the international nomenclature, this factor was later standardized as coagulation factor XII (Factor XII, FXII), but the name Hageman factor is still widely used.
John Hageman's later life provides one of the most striking ironies in medical history for understanding the pathophysiology of this disease. Despite being found to have a coagulation disorder, he never once experienced clinical problems from abnormal bleeding throughout his life. Then in 1968, at only 40 years of age, he died of thrombotic pulmonary embolism. The fact that a person diagnosed as lacking a bleeding factor died instead of thrombosis is spoken of as the event that first clinically suggested the hypothesis that FXII deficiency not only does not increase bleeding risk but may even raise the thrombotic tendency. Of course, a causal relationship cannot be concluded from a single case observation, but reports of increased venous thromboembolism in patients with FXII deficiency later accumulated in a number of epidemiological studies, and Mr. Hageman's case is cited as the symbolic basis of this hypothesis.
During the 1960s–70s, the components of the contact activation pathway were identified one after another. Following FXII, prekallikrein (PK) and high molecular weight kininogen (HMW kininogen) were discovered, and the pathway was established in which FXII undergoes autoactivation when exposed to negatively charged surfaces such as glass, kaolin and ellagic acid and then activates PK and FXI. Because this pathway is essential for the in vitro coagulation reaction (that is, APTT measurement), the APTT is used in clinical laboratories as a functional indicator of the intrinsic pathway. However, as it became established that patients with FXII deficiency, PK deficiency and HMW kininogen deficiency all have no bleeding despite markedly prolonged APTT, the concept that the contact activation pathway is not essential for in vivo hemostasis took hold. Later, in the cell-based model of hemostasis, the emphasis on the role of FXII shifted from hemostasis to innate immunity, inflammation, thrombus formation and cross-regulation with complement activation.
The most notable development in FXII research in the 21st century is its association with hereditary angioedema (HAE) type III. In the early 2000s, Bork et al. reported that FXII gene variants (especially the Thr309Lys or Thr309Arg variant) are associated with a new form of HAE causing recurrent angioedema in women. These variants are understood to act through a mechanism in which FXII is excessively activated, so the kallikrein-bradykinin pathway is continuously activated, resulting in excess production of bradykinin, which increases vascular permeability. This is a clinical problem caused by the exact opposite direction—FXII hyperactivation—from complete FXII deficiency, and it is interesting in that different variant patterns of the same gene cause entirely different diseases. This discovery gave rise to the new disease categories HAE-nC1INH (HAE without C1 inhibitor deficiency) or HAE-FXII and brought the F12 gene to the center of angioedema research.
Factor XII deficiency is caused by pathogenic variants in the F12 gene located on the long arm of chromosome 5 at 5q35.3. The F12 gene spans a genomic region of about 12 kb and consists of 14 exons, and the mature protein FXII is a single-chain protein of 596 amino acids. The mode of inheritance is autosomal recessive, and complete deficiency is expressed only when there are variants on both alleles (homozygous or compound heterozygous). In heterozygous carriers, FXII activity (FXII:C) is reduced to about 40–60% of normal, and the APTT may be mildly prolonged. The types of F12 gene variants reported to date are diverse, including missense, nonsense, splice-site variants and small insertions/deletions, and the HAE-FXII-associated Thr309Lys·Thr309Arg variants are gain-of-function variants causing FXII hyperactivation, distinct from the loss-of-function variants of complete deficiency.
FXII deficiency belongs to the 'contact factor deficiency group', which markedly prolongs the APTT but causes no clinical bleeding. Besides FXII deficiency, this group includes prekallikrein (PK) deficiency (Fletcher factor deficiency) and HMW kininogen (HMWK) deficiency (Fitzgerald·Williams·Flaujeac factor deficiency). All three have in common the absence of clinical bleeding, and they must be considered when differentiating the cause of APTT prolongation discovered incidentally before surgery. FXII deficiency is the most common in this group and also tends to cause the most severe APTT prolongation. In PK deficiency, the APTT tends to shorten progressively as the contact time is prolonged (incubation-dependent correction), which is used for differentiation. HMW kininogen deficiency is the rarest and requires dedicated testing.
Loss-of-function variants (complete deficiency) and gain-of-function variants (HAE-FXII) of the F12 gene arise in the same gene but cause entirely different clinical diseases. In complete deficiency, FXII protein is not synthesized or its plasma concentration is extremely low, so the contact activation pathway is not initiated ex vivo, but in vivo hemostasis is maintained by the tissue factor pathway and platelet activation mechanisms. In HAE-FXII, the Thr309 variant causes the FXII molecule to lose its protective O-glycosylation shield, so it readily autoactivates with mechanical stimuli or blood flow shear stress, and excess FXIIa activates kallikrein, producing excess bradykinin, which increases vascular endothelial permeability through the B2 receptor and causes edema. Patients with complete deficiency do not have HAE, and patients with HAE-FXII do not show a bleeding tendency. These two diseases are a good example of genetic pleiotropy in that they originate from the same gene but show different mechanisms and clinical courses.
In addition to primary (hereditary) FXII deficiency due to congenital F12 gene variants, there are secondary conditions in which FXII activity is reduced on an acquired basis. In reduced liver function (cirrhosis, acute liver failure), synthesis of many coagulation factors synthesized in the liver, including FXII, decreases, so FXII:C can also be reduced. During attacks of HAE due to C1 inhibitor deficiency (HAE-C1INH), FXII levels are sometimes transiently reduced due to continuous consumption via the contact activation pathway. In newborns, plasma concentrations of all coagulation factors are lower than in adults, so FXII:C can also be relatively low. Because such secondary reductions can be clinically difficult to distinguish from hereditary deficiency, confirming whether it is primary through genetic testing or family testing increases diagnostic certainty.
The F12 gene is located on the long arm of chromosome 5 at 5q35.3; its official HGNC symbol is F12 and its Entrez Gene ID is 2161. The total length of the gene is about 12 kb and it consists of 14 exons. The mature FXII protein consists of 596 amino acids (molecular weight about 80 kDa) and, in order from the N-terminus, is composed of a fibronectin type II domain, an EGF-like domain, a fibronectin type I domain, a second EGF-like domain, a kringle domain, a proline-rich region and the C-terminal serine protease domain. The serine protease domain contains the catalytic triad (His393-Asp442-Ser544) and is the center of the enzymatic activity that generates FXIa. This complex multidomain structure enables FXII to interact with various ligands (kallikrein, C1q, heparin, negatively charged surfaces, etc.).
Because FXII deficiency is autosomal recessive, it occurs equally in males and females. Complete deficiency (homozygous or compound heterozygous) requires inheriting a variant allele from each parent, and for two heterozygous parents the probability that a child has complete deficiency is 25% and the probability of being a heterozygous carrier is 50%. Heterozygous carriers (FXII:C about 40–60%) have no clinical symptoms, and APTT prolongation is also minimal, approaching the upper limit of the normal range or mildly prolonged. In genetic counseling, as a rule, FXII:C measurement is recommended for parents and siblings after a diagnosis of complete deficiency, but they are advised that because it has almost no clinical significance, no preventive measures or lifestyle restrictions are needed. However, given that research on thrombotic risk is ongoing, it is realistic to advise heterozygous carriers as well to be careful when thrombotic risk factors (old age, surgery, prolonged immobility, contraceptive use, etc.) overlap.
As described above, in addition to the loss-of-function variants that cause complete deficiency, gain-of-function variants that cause HAE-FXII (mainly Thr309Lys, Thr309Arg) have been reported in the F12 gene. HAE-FXII is inherited in an autosomal dominant manner, so a single variant allele is enough to cause clinical symptoms, and it is characterized in women by symptoms being triggered or worsened by estrogen (oral contraceptives, pregnancy). This is explained by estrogen increasing FXII synthesis in the liver, increasing the absolute amount of the variant molecule, and promoting autoactivation of the variant FXII under conditions of high viscosity and high shear. HAE-FXII is classified as one of the new types of HAE occurring without C1 inhibitor deficiency, and diagnosis requires specific variant testing at the Thr309 site of the F12 gene. It is rare for F12 gain-of-function variants associated with HAE-FXII to be found at the same time in the families of patients with complete FXII deficiency, but it is clinically important to clearly distinguish the two diseases.
The hypothesis that FXII deficiency may increase thrombotic risk is still debated from the standpoint of molecular mechanisms. One hypothesis is that FXII regulates the structure of the fibrin clot in vivo, increasing its susceptibility to fibrinolysis (that is, a separate regulation of fibrin clot structure, not in the direction of inhibiting fibrinolysis via the FXII→FXI→TAFI pathway), and that in FXII deficiency the fibrin network forms a denser structure resistant to lysis, increasing clot persistence. Another hypothesis is that because FXII contributes to vasodilation and inhibition of platelet aggregation through activation of endothelial nitric oxide synthase (eNOS), this antithrombotic function is lost in FXII deficiency. Which mechanism is clinically more important has not yet been established, and large prospective cohort studies are needed.
The exact prevalence of FXII deficiency varies across the literature; complete deficiency (homozygous state, FXII:C <1%) is an extremely rare condition estimated at about 1–2 per million. However, mild deficiency (FXII:C 20–50%) and heterozygous carriers (FXII:C 40–70%) are much more common and make up part of the general population. Some studies report that about 1–3% of healthy blood donors have FXII:C below the lower limit of normal (70 IU/dL), suggesting that mild reductions in FXII:C are not uncommon in the population. World Federation of Hemophilia (WFH) reports list FXII deficiency as the representative contact factor deficiency causing 'APTT prolongation without bleeding,' but because it has no clinical significance, the number of registered patients is often not systematically counted. Because inheritance is autosomal recessive, the male-to-female ratio is 1:1.
Regarding ethnic differences in the prevalence of FXII deficiency, founder effects of specific variants have been reported in some populations. Relatively many cases of below-normal FXII:C have been reported in East Asian populations such as Chinese and Japanese, and there is clinical experience that low FXII:C is not uncommon in the Korean population as well. However, complete deficiency (severe FXII deficiency) is rare even in East Asia, and reported variants either overlap with those in Western literature or include novel variants that have not yet been characterized. A marked concentration of FXII deficiency in a specific ethnic group, like the founder effect of F11 variants in Ashkenazi Jews, has not been established. Therefore, the current literature regards FXII deficiency as a disease that is not confined to a specific ethnicity and is rarely distributed worldwide.
The main context in which FXII deficiency becomes a clinical issue is incidental discovery on routine preoperative coagulation screening. When unexplained APTT prolongation is found on preoperative APTT testing for surgery, a hematology consultation is requested, and FXII deficiency is confirmed in the process. In this context, FXII deficiency is a clinically insignificant coagulation test abnormality, and the key clinical role is to quickly confirm that the situation does not require cancelling surgery or measures such as plasma infusion, thereby preventing unnecessary testing and treatment delays. In Korea, there is no systematic FXII deficiency registry, so accurate domestic prevalence data are lacking. This reflects the reality that many cases discovered incidentally through preoperative APTT abnormalities remain only as simple records without follow-up management.
The association between FXII deficiency and thrombosis has been studied from various perspectives since the 1970s. Mr. Hageman's own death from pulmonary embolism was the first clinical clue, and subsequently published case reports described cases of recurrent stroke, myocardial infarction, deep vein thrombosis and pulmonary embolism in patients with FXII deficiency. However, the limitations of these case reports are selection bias (FXII deficiency was found on testing performed in patients who had developed thrombotic complications) and the absence of control groups. More rigorous controlled studies have not reached a consistent conclusion that FXII deficiency alone meaningfully increases the risk of thrombosis, and large prospective studies are needed on whether FXII deficiency adds further risk when other thrombotic risk factors are present. Current guidelines do not classify FXII deficiency itself as an established risk factor for thrombosis.
Coagulation factor XII (FXII, Hageman factor) is the factor that initiates the intrinsic pathway of blood coagulation, that is, the contact activation pathway. When blood contacts a negatively charged surface (glass, kaolin, collagen of the skin basement membrane, polyphosphates on bacterial surfaces, contaminant particles, etc.), FXII binds to that surface and undergoes autoactivation to generate FXIIa (alpha-FXIIa or beta-FXIIa). FXIIa activates prekallikrein (PK) to kallikrein (Ka) and coagulation factor XI (FXI) to FXIa. In this process, HMW kininogen acts as a non-enzymatic cofactor that brings FXIIa, PK and FXI together on the negatively charged surface, enabling efficient activation. Kallikrein in turn forms a positive feedback loop that further activates FXII, and also cleaves HMW kininogen to release the vasodilatory peptide bradykinin.
The core pathophysiology of FXII deficiency is, paradoxically, that in vivo hemostasis proceeds normally even without FXII. This is supported by two facts. First, the main pathway of in vivo hemostasis is the extrinsic pathway driven by the tissue factor (TF)–FVIIa complex, and this pathway does not depend on FXII. Therefore, even in FXII deficiency, after tissue injury the pathway TF-FVIIa→FX·FIX→FXa·FIXa→prothrombinase complex→thrombin→fibrin operates intact, and an adequate hemostatic clot is formed. Second, in vivo FXI is activated mainly by early thrombin (thrombin-mediated feedback) rather than by FXII, so FXIa generation and the resulting supply of FIXa occur even without FXII. Because of these mechanisms, patients with FXII deficiency do not experience clinical bleeding under any bleeding conditions. Even in experiments with mice with complete deletion of the FXII gene (F12 knockout mouse), no excessive bleeding phenotype appeared.
Although FXII is not involved in hemostasis, it participates in other important biological pathways. Its best-established role is activation of the kallikrein-kinin system. Kallikrein activated by FXIIa cleaves HMW kininogen to release bradykinin, and bradykinin acts through vascular endothelial B2 receptors to cause vasodilation, endothelial nitric oxide production and increased vascular permeability. Therefore, in FXII deficiency, activation of this pathway is reduced, and inflammatory responses and vasodilation may be decreased. FXII also intersects with the fibrinolytic pathway. FXIIa can directly activate a plasminogen activator (urokinase-type plasminogen activator, uPA), through which it may play a role in promoting the lysis of fibrin clots. The hypothesis that, in FXII deficiency, this profibrinolytic function is reduced so that formed fibrin clots may persist longer has been proposed as one molecular explanation for increased thrombotic risk.
More recent studies show that FXII intersects with the complement pathway as part of the innate immune system. FXIIa can directly activate complement component C1 to initiate the classical complement pathway, suggesting that FXII contributes to the early immune response against bacteria and foreign substances. FXIIa also activates monocytes and macrophages and induces cytokine production, and is thus involved in regulating inflammatory responses. These roles show that FXII is a complex regulatory molecule that goes beyond simply being a factor initiating in vitro coagulation reactions, serving as a bridge between innate immunity and the coagulation and fibrinolytic systems. To what extent these functions are weakened in patients with FXII deficiency, and whether this leads to clinically meaningful immune vulnerability, has not yet been sufficiently studied.
The most fundamental clinical feature of factor XII deficiency is that there is no clinical bleeding at all. This is the key feature that gives it a very unique position even among coagulation factor deficiencies. Even when FXII:C is at an unmeasurable level (complete deficiency, <1 IU/dL), patients do not experience any spontaneous bleeding-related symptoms. There is no systematic evidence that excessive bleeding occurs in patients with FXII deficiency even in situations of strong hemostatic stress such as surgery, trauma, tooth extraction and childbirth. This is also an important difference from FXI deficiency (hemophilia C). In FXI deficiency, delayed bleeding at mucosal surgical sites is well known, but such bleeding has not been reported in FXII deficiency. Therefore, it is appropriate to understand FXII deficiency not as a 'bleeding factor deficiency' but as an 'asymptomatic condition that causes coagulation test abnormalities.'
Cases have been reported in the literature in which patients with complete FXII deficiency did not develop excessive bleeding after undergoing various invasive procedures, including major surgery. Even in procedures with high bleeding risk, such as laparotomy, orthopedic replacement surgery, cardiac surgery (including cardiopulmonary bypass) and obstetric and gynecologic surgery (cesarean section, hysterectomy, etc.), patients with FXII deficiency generally showed blood loss within the normal range. This clinical experience supports that patients with FXII deficiency do not need preoperative prophylactic plasma infusion or coagulation factor administration, and international guidelines in fact recommend this approach. Cancelling or postponing surgery on the grounds of bleeding risk in patients with FXII deficiency found to have preoperative APTT prolongation is not justified, and excessive postoperative transfusion can also cause unnecessary iatrogenic complications. Clearly explaining this to the patient and the surgeon is the key role of the hematologist.
Complete FXII deficiency has no bleeding or angioedema symptoms, but in HAE-FXII (gain-of-function variant), described earlier, a different clinical picture appears. Patients with HAE-FXII may develop recurrent cutaneous angioedema (soft non-pitting edema, occurring mainly in the limbs, face, genitals, etc.), abdominal pain (pseudo-acute abdomen due to intestinal angioedema) and upper airway angioedema (laryngeal edema, risk of airway obstruction). These symptoms belong to a disease category entirely separate from complete FXII deficiency, and it should be noted that although they share the same F12 gene, the direction of the variant (loss of function vs. gain of function) differs. If angioedema occurs in a patient with complete FXII deficiency, other causes (allergy, C1-inhibitor deficiency HAE, drug-induced angioedema, etc.) should be considered rather than FXII deficiency itself.
Given that the association with thrombotic risk is controversial, when thromboembolic symptoms appear in patients with FXII deficiency or heterozygous carriers, the relationship with FXII deficiency should be considered. Clinically, when deep vein thrombosis, pulmonary embolism or arterial thromboembolism (stroke, myocardial infarction) occurs in a patient with FXII deficiency, overlap with other thrombotic risk factors (inherited thrombophilia, antiphospholipid antibody syndrome, cancer, prolonged immobilization, hormone therapy, etc.) should be systematically evaluated. Because a causal relationship in which FXII deficiency alone causes thrombosis has not yet been established, it is reasonable to decide whether and for how long to give anticoagulant therapy to patients with FXII deficiency who develop thromboembolism based on the presence and severity of other thrombotic risk factors rather than on FXII deficiency.
The most characteristic laboratory finding in FXII deficiency is marked, dramatic isolated prolongation of the APTT. In complete FXII deficiency, the APTT is markedly prolonged beyond the normal control value (usually 25–35 seconds), exceeding 60 seconds, and in severe cases it may be prolonged to 100 seconds or more. Even compared with PK deficiency or HMW kininogen deficiency in the same contact factor deficiency group, the APTT prolongation tends to be the most extreme. In contrast, the prothrombin time (PT) evaluates only the extrinsic (TF) pathway and is therefore completely normal. Thrombin time (TT), fibrinogen concentration, platelet count and bleeding time (BT or PFA-100) are all normal as well. This pattern—dramatic APTT prolongation with normal PT, TT, platelets and bleeding time—can occur in common in contact factor deficiencies, FVIII, FIX or FXI deficiency, or lupus anticoagulant, so the cause must be identified by single-factor FXII:C assay.
There is a laboratory finding useful for distinguishing FXII deficiency from PK deficiency. In the standard APTT test, the activating reagent (contact substance) and patient plasma are incubated for a short time (usually 3–10 minutes), and then calcium is added and the clotting time is measured. In PK deficiency, however, the APTT tends to shorten progressively as the incubation time is lengthened (e.g., 10 minutes → 30 minutes). This is because, even without PK, FXII is spontaneously activated in small amounts when sufficiently exposed to a negatively charged surface, and the FXIIa that accumulates over time can drive the pathway forward through other factors. In contrast, when FXII itself is deficient, the APTT does not shorten even if the incubation time is prolonged. This incubation-dependent correction is a simple observational tool useful for distinguishing FXII deficiency from PK deficiency.
When plasma from a patient with FXII deficiency and prolonged APTT is mixed 1:1 with normal plasma, the APTT is corrected to within the normal range by the FXII supplied by the normal plasma (i.e., it corrects on the mixing test). This procedure confirms that the prolongation is due to factor deficiency and not to an inhibitor. However, when lupus anticoagulant (LA) or another inhibitor is present, the APTT does not correct after mixing, so the mixing result allows initial differentiation between deficiency and an inhibitor. After correction on mixing is confirmed, single-factor FXII:C assay (one-stage APTT-based method) is performed to quantify FXII:C; in complete deficiency, FXII:C is measured below 1 IU/dL or reported as undetectable. Checking for abnormal protein synthesis itself by FXII antigen (FXII:Ag) ELISA allows distinction between type I (CRM−, no protein produced) and type II (CRM+, nonfunctional protein produced).
On whole-blood viscoelastic coagulation tests such as thromboelastography (TEG) or rotational thromboelastometry (ROTEM), patients with FXII deficiency generally show results within the normal range. Because these tests evaluate actual hemostatic function in whole blood, this reflects that FXII deficiency, which markedly prolongs the APTT, does not affect the actual ability to form fibrin clots. This means that when massive intraoperative bleeding occurs and goal-directed hemostatic therapy is guided by TEG/ROTEM results, the presence of FXII deficiency does not complicate treatment decisions. Also, on the thrombin generation assay (TGA), the thrombin-generating capacity of patients with FXII deficiency (peak thrombin, endogenous thrombin potential, etc.) appears normal under starting conditions that do not activate FXII (TF-triggered).
Clinical discovery of FXII deficiency almost always occurs through incidental discovery of APTT prolongation on routine coagulation testing before surgery or invasive procedures. Because there are no bleeding symptoms, it is very rare for patients to seek out a hematologist on their own. The APTT is performed as part of anesthesia pre-assessment or routine preoperative testing, and when the result is found to be markedly prolonged beyond the normal reference value, the attending physician requests a hematology consultation. What matters in this consultation is to quickly identify the cause of the APTT prolongation and clearly determine whether it increases surgical bleeding risk. Rapidly distinguishing conditions that prolong the APTT but do not increase surgical bleeding risk, such as FXII deficiency, PK deficiency, HMW kininogen deficiency and lupus anticoagulant, can prevent surgical delays and unnecessary administration of blood products.
When marked preoperative APTT prolongation (normal PT, normal TT, normal bleeding time) is confirmed, the following stepwise differential process is followed. First, FVIII:C, FIX:C, FXI:C are measured to identify intrinsic pathway deficiencies with clinical bleeding risk (hemophilia A, B, C). If these are normal, the contact factor group (FXII:C, PK:C, HMWK:Ag) is measured. If FXII:C is markedly reduced and the remaining factors are normal, FXII deficiency can be diagnosed. In addition, APTT prolongation due to antiphospholipid antibodies is differentiated by lupus anticoagulant (LA) screening. When FXII deficiency is confirmed, since there is no surgical bleeding risk, it can be recommended that surgery proceed as scheduled without separate preventive measures. Because the accessibility of single-factor FXII:C testing and laboratory turnaround time affect the surgical schedule in this rapid differential process, close communication with the clinical hematology laboratory is important.
While waiting for single-factor test results, or in settings where access to specialized testing is limited, the pattern of APTT change when the APTT incubation time is lengthened can provide preliminary differential information. In PK deficiency, the APTT tends to shorten when plasma is incubated with the contact activator for 30 minutes or longer, but in FXII deficiency, this APTT shortening with prolonged incubation does not occur. This simple observation provides a clue for preliminarily distinguishing the two contact factor deficiencies even without FXII:C testing. However, because this technique is not a standardized test and results may vary with reagents, instruments and incubation conditions, it should be used only as a reference observation, and the final diagnosis must be confirmed by single-factor assay.
In patients with confirmed FXII deficiency, it is important to check whether the patient or family members have a history of recurrent angioedema (especially in the upper limbs, face, abdomen and larynx). HAE-FXII (F12 gain-of-function variant) is a different disease from complete FXII deficiency, but because it arises from the same gene, cases of angioedema in the family should be investigated to understand the overall context of FXII-related disorders. If angioedema symptoms coexist in a patient with reduced FXII:C, C1-inhibitor deficiency HAE or other causes should be differentiated first rather than FXII deficiency itself, and the presence of an F12 gain-of-function variant should also be reviewed. Coexistence of these two conditions is rare, but they can be clearly distinguished by genetic testing.
The standard algorithm for definitive diagnosis of FXII deficiency is as follows. Step 1: Confirm marked APTT prolongation found preoperatively or incidentally, and at the same time confirm that PT, TT, platelets and fibrinogen are normal. Step 2: Perform a mixing test (patient plasma + normal plasma 1:1) to check whether the APTT corrects (correction: possible factor deficiency; no correction: possible inhibitor or lupus anticoagulant). Step 3: If corrected on the mixing test, measure FVIII:C, FIX:C and FXI:C to first exclude factor deficiencies with clinical bleeding risk. Step 4: If these are normal, measure FXII:C, PK:C and HMWK:Ag in sequence to identify the contact factor deficiency. FXII:C <50 IU/dL is classified as FXII deficiency, and <1 IU/dL as complete deficiency. Step 5: Consider family testing and F12 gene analysis to confirm the diagnosis and determine whether it is inherited.
The standard single-factor FXII:C assay is the one-stage APTT-based method using FXII-deficient substrate plasma. This method mixes substrate plasma (FXII-deficient plasma) with dilutions of patient plasma and quantifies FXII:C by measuring the degree of APTT shortening proportional to the amount of patient FXII supplied. The quality of the FXII-deficient substrate plasma is important for measurement accuracy, and confirming that the FXII-deficient substrate is actually deficient only in FXII with other factors normal ensures reliability. When interpreting results, sensitivity to FXII deficiency may differ depending on the type of APTT reagent, and some reagents may classify a mild FXII reduction as normal. Accurate construction of dilution curves is needed to clearly distinguish complete deficiency (FXII:C <1%) from heterozygous carriers (FXII:C 40–70%).
When FXII:C is clinically markedly reduced, F12 gene sequencing can be performed for definitive diagnosis and family screening. Pathogenic variants throughout the F12 gene are identified by Sanger sequencing or next-generation sequencing (NGS)-based bleeding panels. Gene analysis is used not only for definitive diagnosis but also for determining carrier status, prenatal diagnosis (if needed) and predicting the functional significance of variants. If a pathogenic variant is identified on F12 gene analysis, testing of parents and siblings can be recommended according to the mode of inheritance (autosomal recessive). Because the clinical significance of FXII deficiency itself is very low, the clinical need for genetic testing is not great, but identifying the variant is useful for family counseling and long-term follow-up. When HAE-FXII is suspected, it is efficient to test specifically for Thr309 variants.
The important conditions to be differentiated in the final diagnosis of FXII deficiency are summarized as follows. When reduced FVIII:C is present, hemophilia A or vWD type 2N (von Willebrand disease type 2N, FVIII binding site variant) is considered. When reduced FIX:C is present, hemophilia B is confirmed. When reduced FXI:C is present, it is hemophilia C. When all three of these factors are normal and only FXII:C is reduced, FXII deficiency can be confirmed. APTT prolongation due to lupus anticoagulant (LA) does not correct on the mixing test and is therefore easily differentiated at this step. Because there is additional thrombotic risk when antiphospholipid antibodies are present, it is recommended to check lupus anticoagulant together with anticardiolipin and anti-β2GP1 antibodies in patients with incidentally discovered APTT prolongation.
The most central principle regarding the treatment of FXII deficiency (Hageman factor deficiency) is that bleeding treatment is unnecessary. Because clinical bleeding does not occur, there is no indication for coagulation factor replacement (FFP, cryoprecipitate, recombinant factors, etc.) to stop or prevent bleeding. This is the clinical characteristic that fundamentally distinguishes FXII deficiency from all other coagulation factor deficiencies (FVIII, FIX, FXI, FVII, FX, FV, etc.). Administering fresh frozen plasma (FFP) for preoperative prophylaxis is also not recommended, because FXII deficiency does not increase surgical bleeding risk. On the contrary, unnecessary FFP administration adds the risk of transfusion-related complications (allergic reactions, TRALI, risk of viral transmission, volume overload, etc.) and should be avoided. There is currently no approved treatment that specifically replaces FXII, and no treatment is in development.
The most important clinical action before surgery in a patient with FXII deficiency is to clearly communicate to the surgical team that FXII deficiency does not increase bleeding risk. When APTT prolongation is found on preoperative coagulation testing, the surgical team requests a hematology consultation, and after confirming FXII deficiency by single-factor testing, the hematologist clearly communicates the following to the surgical team: ①FXII deficiency is not essential for in vivo hemostasis and does not increase surgical bleeding risk; ②preoperative FFP or other blood products are unnecessary; ③there is no reason to change the surgical schedule; ④no additional coagulation monitoring is needed beyond routine postoperative bleeding surveillance. When this clear communication takes place, unnecessary surgical delays, excessive administration of blood products and patient anxiety can be prevented. It is also important to fully explain to the patient that their condition is clinically harmless, to ease fear of medical care.
Given that the association between FXII deficiency and thrombotic risk is controversial, the indication for thromboprophylaxis is determined not by FXII deficiency itself but by the presence and severity of other thrombotic risk factors. When a patient with FXII deficiency is in a standard high-risk situation for venous thromboembolism, such as surgery, prolonged immobilization or cancer, standard prophylactic anticoagulation (low-molecular-weight heparin, unfractionated heparin, etc.) is applied as in the general population. Conversely, long-term anticoagulation on the grounds of FXII deficiency itself is not recommended in current guidelines. When venous thromboembolism occurs in a patient with FXII deficiency, the indication, duration and intensity of anticoagulation are determined by the site of thrombosis, whether it is recurrent, and the presence of other inherited thrombophilias (FV Leiden, prothrombin G20210A, protein C, protein S or antithrombin deficiency, etc.).
In HAE-FXII (gain-of-function variant), which is distinct from complete FXII deficiency, separate treatment principles apply. The treatment goals of this disease are prevention of angioedema attacks caused by excessive bradykinin production and rapid treatment during attacks. For acute attack treatment, icatibant (bradykinin B2 receptor antagonist), ecallantide (kallikrein inhibitor) and C1-inhibitor concentrate (used off-label for non-HAE-C1INH types) are used. For long-term prophylaxis, discontinuation of estrogen-containing oral contraceptives and hormone replacement therapy, tranexamic acid or switching to estrogen-free contraception, and, for frequent attacks, lanadelumab (anti-kallikrein monoclonal antibody) or subcutaneous C1-inhibitor injection are considered. Patients with complete FXII deficiency do not need these treatments, and clearly distinguishing HAE-FXII from complete deficiency is key to preventing inappropriate treatment.
The bleeding-related prognosis of FXII deficiency is the most favorable of all coagulation factor deficiencies and is essentially the same as that of the normal population. Patients with FXII deficiency do not experience any bleeding complications, and their risks of spontaneous bleeding, excessive postoperative bleeding and increased bleeding during childbirth are no higher than those of the general population. The serious chronic complications of hemophilia A and B, such as hemophilic arthropathy due to hemarthrosis, pseudotumors due to muscle hematomas and intracranial hemorrhage, do not occur in FXII deficiency. Therefore, patients with FXII deficiency are not subject to any lifestyle restrictions for a bleeding disorder and can normally carry out all daily activities, including contact sports, physical activity and surgical treatment. Regular hematologic follow-up is generally not needed either.
The only uncertainty in the prognosis of FXII deficiency is its relationship with the risk of thrombotic complications. As mentioned above, some case reports, including Mr. Hageman's death from pulmonary embolism, suggest an increased frequency of thrombotic events in patients with FXII deficiency, but this relationship has not been consistently established in large prospective cohort studies. The current medical consensus is that FXII deficiency alone does not cause a clinically meaningful increase in thrombotic risk, and that in patients with FXII deficiency who experience thrombotic events, the coexistence of other thrombotic risk factors should be evaluated first. Therefore, creating excessive anxiety about thrombotic risk in patients with FXII deficiency or prescribing excessive prophylactic anticoagulation is not justified at the current level of evidence.
The prognosis of patients with HAE-FXII, rather than complete FXII deficiency, is determined by the frequency and severity of angioedema attacks. In patients with HAE-FXII, laryngeal edema is a potentially fatal complication that carries a risk of death by asphyxiation due to airway obstruction. Cases have also been reported in which recurrent abdominal pain attacks in inadequately diagnosed and managed HAE-FXII patients led to unnecessary surgery (such as laparotomy for suspected appendicitis). However, this is the prognosis of HAE-FXII, not complete FXII deficiency, and the two F12-related conditions must always be clearly distinguished. For patients with complete FXII deficiency, the correct clinical understanding is that there is no difference from the normal population in all the prognostic aspects described in this section.
Because the main context in which FXII deficiency is diagnosed is incidental preoperative discovery, patients often experience considerable anxiety when they are first told they 'have a coagulation disorder.' Therefore, at the time of diagnosis the hematologist should explain clearly and fully that this condition is clinically harmless, requires no restrictions on surgery or daily life, and does not affect life expectancy or quality of life. However, because APTT prolongation may be found repeatedly whenever the patient undergoes surgery at other medical institutions in the future, it is practical to provide a brief medical note or medical information card so that the patient can explain their condition (FXII deficiency, no bleeding risk) to the attending physician. Regular follow-up is generally not needed, and patients are advised to revisit a hematologist when new symptoms develop or a thrombotic event is suspected.
Because FXII deficiency does not increase clinical bleeding risk, no special measures are needed to prevent bleeding. Preventive measures recommended in hemophilia A and B—prophylactic coagulation factor administration (prophylaxis), prophylactic plasma infusion before tooth extraction or surgery, restriction of aspirin and NSAIDs, avoidance of contact sports, avoidance of intramuscular injections, etc.—do not apply to FXII deficiency. If the patient has other medical indications requiring antiplatelet agents (aspirin, clopidogrel, etc.) or anticoagulants (warfarin, NOAC), these can be given at standard doses regardless of the presence of FXII deficiency. The bleeding risk from these drugs is also not aggravated by FXII deficiency.
The most important preventive action before surgery in patients with FXII deficiency is to prevent unnecessary administration of blood products and interventions. In the past, patients with APTT prolongation were sometimes given prophylactic fresh frozen plasma (FFP) or had surgery postponed without the cause being determined, leading to adverse effects such as plasma-related complications, increased costs and surgical delays. Once a diagnosis of FXII deficiency is established, clearly recording "FXII deficiency: no clinical bleeding risk, preoperative FFP unnecessary" in the medical record (electronic medical record) can prevent the same situation from recurring at other medical institutions later. The patient is also given a brief summary document explaining their condition, to use in explaining it to other medical staff in emergencies.
For prevention related to thrombotic risk, FXII deficiency itself is not managed as a special risk factor, and the thromboprophylaxis principles applied to the general population are applied in the same way. These include elastic compression stockings and adequate hydration during long flights or prolonged immobilization, early postoperative mobilization, management of thrombotic risk factors such as obesity, smoking and hypertension, and short-term prophylactic low-molecular-weight heparin when needed. Whether FXII deficiency itself confers additional thrombotic risk when using estrogen-containing oral contraceptives has not been established, but in patients with a family history of HAE-FXII it is reasonable to consider avoiding estrogen. In patients with antiphospholipid antibody syndrome accompanied by FXII deficiency, the thrombotic risk management principles of antiphospholipid antibody syndrome itself are followed.
Genetic counseling is recommended for first-degree relatives of patients diagnosed with FXII deficiency. Counseling covers the autosomal recessive mode of inheritance, the possibility that parents and siblings are heterozygous carriers, the possibility of deficiency in children, and the fact that FXII deficiency is clinically harmless. Family testing (FXII:C measurement) can be recommended, but because it has no clinical significance there is no reason to insist on testing. When a couple planning pregnancy are both confirmed to be carriers with reduced FXII:C, there is a possibility (25%) of complete FXII deficiency in their child, but it should be clearly explained that because this condition is clinically harmless, it is not an indication for prenatal diagnosis or preimplantation genetic testing.